ArticleTheranostics2020
Nanozyme-assisted sensitive profiling of exosomal proteins for rapid cancer diagnosis.
Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Nanozymes: bridging nanoscale characteristics and catalytic mechanisms for advanced biomedical applications.Journal of enzyme inhibition and medicinal chemistry · 2026Review
- Advances in Extracellular Vesicle-Based Surface-Enhanced Raman Spectroscopy for Cancer Diagnosis.Biosensors · 2026Review
- Review
- Emerging biomarkers for early cancer detection and diagnosis: challenges, innovations, and clinical perspectives.European journal of medical research · 2025Review
- Exosomal biomarkers: A novel frontier in the diagnosis of gastrointestinal cancers.World journal of gastrointestinal oncology · 2025Review
- Innovative Applications of Nanopore Technology in Tumor Screening: An Exosome-Centric Approach.Biosensors · 2025Review
- Rapid evaluation of hepatocellular carcinoma by detecting plasma exosomes with time-resolved fluorescence immunochromatographic test strips.Mikrochimica acta · 2024Article
- The new advance of exosome-based liquid biopsy for cancer diagnosis.Journal of nanobiotechnology · 2024Review
- Recent Advances in Microfluidic-Based Extracellular Vesicle Analysis.Micromachines · 2024Review
- Recent Trends and Innovations in Bead-Based Biosensors for Cancer Detection.Sensors (Basel, Switzerland) · 2024Review
- Article
- Plasma-derived exosomal miR-326, a prognostic biomarker and novel candidate for treatment of drug resistant pediatric acute lymphoblastic leukemia.Scientific reports · 2024Article
- Extracellular vesicle-based liquid biopsy biomarkers and their application in precision immuno-oncology.Biomarker research · 2023Review
- Exploiting targeted nanomedicine for surveillance, diagnosis, and treatment of hepatocellular carcinoma.Materials today. Bio · 2023Review
- Glypican-3 (GPC-3) Structural Analysis and Cargo in Serum Small Extracellular Vesicles of Hepatocellular Carcinoma Patients.International journal of molecular sciences · 2023Article
- Cell-Free DNA as a Surveillance Tool for Hepatocellular Carcinoma Patients after Liver Transplant.Cancers · 2023Review
- Engineering Cell Membrane-Cloaked Catalysts as Multifaceted Artificial Peroxisomes for Biomedical Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Nanomaterials for Molecular Detection and Analysis of Extracellular Vesicles.Nanomaterials (Basel, Switzerland) · 2023Review
- Advances of multi-omics applications in hepatic precancerous lesions and hepatocellular carcinoma: The role of extracellular vesicles.Frontiers in molecular biosciences · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The proteins expressed on exosomes have emerged as promising liquid-biopsy biomarkers for cancer diagnosis. However, molecular profiling of exosomal proteins remains technically challenging. Herein, we report a nanozyme-assisted immunosorbent assay (NAISA) that enables sensitive and rapid multiplex profiling of exosomal proteins. This NAISA system is based on the installation of peroxidase-like nanozymes onto the phospholipid membranes of exosomes, thus avoiding the need for post-labelling detection antibodies. The exosomal proteins are determined by a sensitive nanozyme-catalyzed colorimetric assay less than 3 h, without the need for multi-step incubation and washing operations. Using NAISA to profile exosomal proteins from different cell lines and clinical samples, we reveal that tumor-associated exosomal proteins can serve as promising biomarkers for accurate cancer diagnosis in a cooperative detection pattern.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.